Product image of Ondansetrón Aurovitas (Ondansetron) supplied by GNH India

Ondansetrón Aurovitas

Active Ingredient:
Ondansetron
Origin:
EU

Ondansetrón Aurovitas (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón Aurovitas, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH India supplies Ondansetrón Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondansetron is used in the management of nausea and vomiting pathways related to several clinical settings.

  • Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes.
  • Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms.
  • Post‑operative nausea and vomiting: decreases the incidence of vomiting after surgery.

How It Works

  • Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated activation of the vomiting centre, thereby reducing nausea and vomiting signals.

Side Effects

Side effects reported with ondansetron are generally mild to moderate and vary by patient population.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Diarrhoea: loose stools.
  • Fatigue: feeling of tiredness.
  • Dizziness: light‑headed sensation.

Serious or Rare Side Effects

  • QT interval prolongation: cardiac rhythm changes detectable on ECG.
  • Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents.
  • Hepatic dysfunction: elevated liver enzymes.
  • Severe constipation or intestinal obstruction.
  • Vision changes: blurred vision or visual disturbances.

Precautions & Warnings

When using ondansetron, clinicians should consider several safety aspects.

  • Cardiac monitoring: assess baseline ECG in patients with known cardiac disease.
  • Electrolyte balance: correct hypokalaemia or hypomagnesemia before use.
  • Drug interactions: review concomitant medications that affect QT interval.
  • Pregnancy: weigh benefits against potential risks; use only if clearly needed.
  • Breastfeeding: monitor infant for possible effects if mother continues therapy.
  • Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Avoid Interactions

Ondansetron may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Amiodarone: combined use can markedly increase QT prolongation risk.
  • Certain anti‑arrhythmics (e.g., sotalate, procainamide): additive effect on cardiac repolarisation.
  • Serotonergic agents (e.g., tramadol, linezolid): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (ketoconazole, fluconazole): may increase ondansetron plasma levels.
  • Macrolide antibiotics (erythromycin, clarithromycin): modest effect on QT interval.
  • CYP3A4 inhibitors (cimetidine, grapefruit juice): can raise drug exposure.
  • Digoxin: potential for altered serum concentrations.
  • Metoclopramide: overlapping anti‑emetic mechanisms may require dose adjustment.

Frequently Asked Questions

Ondansetrón Aurovitas contains ondansetron, which is prescribed to prevent and treat nausea and vomiting that can occur after chemotherapy, radiation therapy, or surgery. It is used in both adult and pediatric patients when these emetogenic triggers are present.

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. This inhibition stops serotonin‑driven signals from activating the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The specific dose of Ondansetrón Aurovitas is determined by the prescribing clinician based on the patient’s age, weight, type of emetogenic stimulus, and overall medical condition. Healthcare professionals follow established guidelines to set the appropriate regimen.

Ondansetron is classified as pregnancy category B in many regions, indicating no proven risk in animal studies but limited human data. It should be used only if the potential benefit justifies the potential risk to the fetus. While small amounts are excreted in breast milk, clinicians usually consider it compatible with breastfeeding if benefits outweigh risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering a targeted mechanism compared with dopamine antagonists (e.g., metoclopramide) or antihistamines (e.g., diphenhydramine). It is generally more effective for chemotherapy‑induced nausea and has a lower risk of extrapyramidal side effects, though QT prolongation requires cardiac monitoring.

Store the product at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Ondansetrón Aurovitas is administered orally, typically as a tablet or oral solution, depending on the formulation supplied. The medication should be taken with or without food as directed by the prescriber, and the exact timing relative to chemotherapy or surgery is guided by clinical protocols.

The most serious risks include QT interval prolongation, which can lead to serious cardiac arrhythmias, and rare cases of severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of cardiac irregularities, especially if they have existing heart conditions or are taking other QT‑prolonging drugs.

Ondansetron is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Caution is also advised for patients with congenital long‑QT syndrome, significant electrolyte disturbances, or those taking multiple medications that prolong the QT interval.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT